ArticleInfection2026
Metagenomic next-generation sequencing assists in identifying neurosyphilis: a case series.
Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neurosyphilis presenting as status epilepticus and hemiplegia diagnosed by metagenomic next-generation sequencing: A case report.Experimental and therapeutic medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundNeurosyphilis is a severe manifestation of syphilis caused by Treponema pallidum and remains challenging to diagnose because of heterogeneous clinical presentations and the limited performance of cerebrospinal fluid (CSF) assays. Here, we report four neurosyphilis cases in which CSF metagenomic next-generation sequencing (mNGS) detected T. pallidum and explore its potential value as an adjunctive diagnostic tool.
methodsWe retrospectively reviewed four HIV-negative adults treated at the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University in whom CSF mNGS detected T. pallidum and the overall clinical assessment supported neurosyphilis. Demographic data, presentations, neuroimaging, CSF parameters, serology, antimicrobial therapy, and outcomes were extracted from the medical records.
resultsAll patients had positive syphilis serology and inflammatory CSF profiles with lymphocytic pleocytosis (40-130 cells/µL) and elevated CSF protein (0.70-1.26 g/L). Brain magnetic resonance imaging (MRI) revealed non-specific chronic structural changes in all patients (including white matter hyperintensities, cerebral atrophy, and ventricular enlargement), with no acute ischemic, hemorrhagic, or neoplastic lesions. Bacterial cultures remained negative after 48 h. CSF mNGS detected T. pallidum in all cases (unique reads 8-135; standardized mapped reads number (SMRN) 1-53; genome coverage 0.0260-0.4945%), including three patients whose predominant presentations were neuropsychiatric. Following anti-treponemal therapy with ceftriaxone or penicillin, all patients showed clinical improvement.
conclusionsIn this case series, CSF mNGS provided direct detection of T. pallidum and supported the diagnosis of neurosyphilis in patients with diverse, often neuropsychiatric presentations when conventional microbiology was non-diagnostic. CSF mNGS may serve as a useful adjunct in selected patients, but results should be interpreted alongside clinical features and CSF inflammation rather than in isolation.
Indexed as
Identifiers
42390736What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.